{
  "docId": "019de076-b3a4-71cc-8183-985590ab9557",
  "docSlug": "2fc842fd1dad3dbfa44767764fb3543f",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 21 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 21,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a Vitruvian-man style silhouette to represent the breadth of therapeutic applications.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b3a4-71cc-8183-985590ab9557/14",
  "deckHref": "/decks/019de076-b3a4-71cc-8183-985590ab9557",
  "deckJsonHref": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json",
  "deckAnchorHref": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.68,
        "y": 0.58
      },
      "kind": "callout",
      "text": "First MaxCyte-Enabled Therapy is Approved CASGEVY for Sickle Cell Disease (UK + US) for Beta-Thalassemia (UK) UK MHRA Nov 2023 US FDA Dec 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16211b51-97bd-4971-a7ff-5a6db57154d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.215,
        "x": 0.228,
        "y": 0.298
      },
      "kind": "image",
      "text": "Human silhouette graphic",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d41c9ad-77bd-4064-add5-1ce1d5d60e7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Genetic Diseases: Beta-Thalassemia, Sickle Cell Disease, Chronic Granulomatous Disease (CGD); Solid Tumors: Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Other Solid Tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09a0b3b2-3e18-4a87-af1c-d1c1445c3af7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.7,
        "y": 0.25
      },
      "kind": "list",
      "text": "ARCUS, Base-editing (CRISPR), CRISPR, RNA-Based Engineering, TALENS, Zinc Finger Nucleases (ZFNs)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b18e27e2-9270-4765-bf54-619b12f06029",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.45,
        "y": 0.25
      },
      "kind": "list",
      "text": "Infectious Disease: HIV; Hematological Malignancies: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, T Cell Lymphoma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9052438-3f49-4e44-b542-439e954bc638",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "metric",
      "text": "1,000+ Patients in active clinical trials enabled by MaxCyte",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d06b651-80d0-4c50-ba21-73412c78cd01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "MaxCyte Enables Next-Generation Cell Therapies Across a Variety of Diseases",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "863906c7-a8f9-4525-a0a6-a5d503f72174",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "20c42468-2c81-4751-a1f9-a6ba473e7c5e",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Traction is showcased from pages 7-14.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 7,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "860b177a-a306-4d07-b9f0-f03de41e9887",
      "evidence": "The traction section highlights the benefits of partnering with MaxCyte.",
      "position": 1,
      "objective": "What are the benefits of partnering with MaxCyte?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}